ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 41 filers reported holding ONCOCYTE CORP in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $45,000 | -34.8% | 29,874 | -6.6% | 0.00% | – |
Q4 2021 | $69,000 | -41.0% | 31,978 | -2.9% | 0.00% | -100.0% |
Q3 2021 | $117,000 | -48.7% | 32,934 | -17.1% | 0.00% | 0.0% |
Q2 2021 | $228,000 | +5.6% | 39,708 | -4.4% | 0.00% | 0.0% |
Q1 2021 | $216,000 | +148.3% | 41,541 | +13.6% | 0.00% | – |
Q4 2020 | $87,000 | +67.3% | 36,564 | -2.8% | 0.00% | – |
Q3 2020 | $52,000 | +2.0% | 37,614 | +42.2% | 0.00% | – |
Q2 2020 | $51,000 | +59.4% | 26,457 | +99.7% | 0.00% | – |
Q1 2020 | $32,000 | +6.7% | 13,247 | -1.6% | 0.00% | – |
Q4 2019 | $30,000 | +3.4% | 13,460 | -0.8% | 0.00% | – |
Q3 2019 | $29,000 | -14.7% | 13,574 | -0.7% | 0.00% | – |
Q2 2019 | $34,000 | +580.0% | 13,668 | +456.5% | 0.00% | – |
Q1 2018 | $5,000 | -58.3% | 2,456 | -5.1% | 0.00% | – |
Q4 2017 | $12,000 | -33.3% | 2,588 | +7.3% | 0.00% | – |
Q3 2017 | $18,000 | +50.0% | 2,413 | +8.1% | 0.00% | – |
Q2 2017 | $12,000 | -99.8% | 2,233 | +46.5% | 0.00% | – |
Q1 2016 | $7,000,000 | – | 1,524 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 17,349,945 | $25,851,000 | 1.86% |
Defender Capital, LLC. | 2,562,130 | $4,001,000 | 1.39% |
PURA VIDA INVESTMENTS, LLC | 12,223,953 | $18,214,000 | 0.59% |
Penbrook Management LLC | 578,150 | $861,000 | 0.56% |
ACT CAPITAL MANAGEMENT, LLC | 330,000 | $492,000 | 0.52% |
Orbimed Advisors | 3,493,800 | $5,206,000 | 0.08% |
CALIBER WEALTH MANAGEMENT, LLC | 75,120 | $112,000 | 0.07% |
Fort Sheridan Advisors LLC | 135,000 | $201,000 | 0.06% |
AWM Investment Company, Inc. | 241,867 | $360,000 | 0.05% |
WEALTH EFFECTS LLC | 49,000 | $73,000 | 0.03% |